Bilibili Inc Announces 2020 Fourth Quarter and Fiscal Year Financial Results benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March. Details of the conferences and management presentation are as follows:
H.C. Wainwright Global Life Sciences Conference (Virtual)
Presentation: Tuesday, March 9, 2021 at 7:00 a.m. EST
Presenter: Mr. Jielun Zhu, Director and Chief Financial Officer
Webcast link: https://journey.ct.events/view/82bf84ac-4e9c-4ebd-baab-b0bf034e93af. The webcast will also be available under Event Calendar on IMAB s IR website at http://ir.i-mabbiopharma.com/.
Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., Feb. 10, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with advanced solid tumors.
TJ210/MOR210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1 (C5aR1). Produced in the tumoral microenvironment, its ligand C5a acts as a chemoattractant to recruit tumor-promoting cells such as myeloid-derived suppressor cells, M2 macrophages and neutrophils. TJ210/MOR210 is designed to
Press release content from PR Newswire. The AP news staff was not involved in its creation.
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
February 5, 2021 GMT
I-MAB Logo (PRNewsfoto/I-Mab Biopharma)
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors. The Company plans to present detailed clinical results at select scientific conferences this year.